ABVC BioPharma, Inc. (ABVC)

Nasdaq: ABVC · Pharmaceutical Preparations · Fremont, CA · filing with the SEC since 2002

Full chart Alerts Compare

Grade3.0

◀ Past 1.3● Present 3.6▶ Future 3.4

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of ABVC BioPharma, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.0/10

◀ Past1.325% of the headline

● Present3.635% of the headline

▶ Future3.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.3/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.1/10

Has it survived what it has been through?

37 warning events since 2017; the latest 2026-07-02.

weight 22% of this tense · 2nd percentile among 497 sector filers · read for itself

From the record

ABVC BioPharma, Inc.'s filings since 2017 show 37 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 11 times, the latest 2025-05-14); a warning not to rely on past financial statements (8-K item 4.02, 5 times, the latest 2026-03-03); an auditor change (8-K item 4.01, 6 times, the latest 2026-07-02); a late-report notice (Form NT 10-K or NT 10-Q, 15 times, the latest 2026-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.2/10

What has it actually done, year after year?

-40.1% a year over 3 filed years; profitable in 0 of 10.

weight 45% of this tense · 12th percentile among 323 sector filers · read for its customers

From the record

ABVC BioPharma, Inc.'s 3 filed years say what it did: revenue went from $50 million in fiscal 2015 to $296 thousand in fiscal 2025, down 40.1% a year; it rose in 0 of 1 years; the deepest fall was 100% from fiscal 2015 to fiscal 2024; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-40.1%bottom 5% of its family
the share of years revenue rosebottom 4% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.3/10

How has it treated the people who own it?

SI estimate 2.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 23rd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ABVC BioPharma, Inc.'s shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.6/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.5/10

Is it financially healthy right now?

ROE -71%: lost 71¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.

weight 45% of this tense · 35th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, ABVC BioPharma, Inc. lost about 71 cents for every dollar of shareholders' money. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 72.3% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 36% of its family
return on equitybottom 40% of its family
the share count against the year beforebottom 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.5/10

How strong is its position in its industry?

bottom 15% of 315 in its family; net margin -2671.8%.

weight 22% of this tense · 15th percentile among 315 sector filers · read for its customers

From the record

ABVC BioPharma, Inc.'s standing among 315 graded names in its industry family: revenue of $296 thousand in fiscal 2025 ranks in the bottom 13% by size; a net margin of -2671.8% ranks in the bottom 21%; revenue growth of -40.1% a year over the last 2 filed years ranks in the bottom 12% (its annual reports).

What it rests on

revenue against the family$296,000bottom 13% of its family
net margin-2671.8%bottom 21% of its family
three-year revenue growth-40.1%bottom 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ABVC BioPharma, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

2.7/10

How much room does it have to grow?

bottom 27% of 273 in its family for room to expand.

weight 33% of this tense · 27th percentile among 273 sector filers · read for itself

From the record

ABVC BioPharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $681 thousand against no long-term debt tagged leaves 3.2% of its assets as net cash, bottom 17% of its family; cash from operations less capital spending is -1008.9% of revenue (bottom 24%); research spending of 40.9% of revenue (bottom 39%) (its annual report).

What it rests on

cash less debt against assets3.2%bottom 17% of its family
cash from operations less capital spending against revenue-1008.9%bottom 24% of its family
research spending against revenue40.9%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.1/10

What could actually drive growth from here?

bottom 31% of 306 in its family for growth drivers.

weight 45% of this tense · 31st percentile among 306 sector filers · read for its customers

From the record

ABVC BioPharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -40.1% a year over the last three filed years against -40.1% over all 3, speeding up (top 40% of its family); research spending grew -64.4% a year (bottom 2%) (its annual reports). ABVC BioPharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
three-year growth of research spending-64.4%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ABVC BioPharma, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ABVC · research, not advice